RenovoRx Inc.

Last updated September 27, 2026

Organization details

Legal name
RenovoRx Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
3841 — Surgical & Medical Instruments & Apparatus
Jurisdiction of incorporation
Delaware
Headquarters city
Mountain View
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
RNXT
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001574094
EIN
27-1448452

Board of directors

Chief executives

Shaun Bagai · CEO
Dates unknown

Director election results

Annual meeting of June 25, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

2 of this board's directors also sit on 4 other boards. 3 are in the same sector.

Network of RenovoRx Inc.'s board connections Bio Green Med Solution Inc. Bio Green Med Solution... Ernexa Therapeutics Inc. Ernexa Therapeutics In... Geron Corporation Geron Corporation Quince Therapeutics Inc. Quince Therapeutics In... Robert J. Spiegel Robert J. Spiegel Una S. Ryan Una S. Ryan RenovoRx Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$84,494
13 purchases by 4 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Sep 10, 2026 VOLL MARK Officer (Chief Financial Officer) Grant or award +80,000 — —
May 19, 2026 VOLL MARK Officer (Chief Financial Officer) Open-market purchase +25,000 $0.79 $19,750
Apr 3, 2026 VOLL MARK Officer (Chief Financial Officer) Grant or award +80,000 — —
Mar 25, 2026 VOLL MARK Officer (Chief Financial Officer) Grant or award +12,380 — —
Mar 20, 2026 Laurence Marton Director Open-market purchase +9,720 — —
Mar 20, 2026 Shaun Bagai Director, Officer (Chief Executive Officer) Open-market purchase +24,300 — —
Mar 20, 2026 VOLL MARK Officer (Chief Financial Officer) Open-market purchase +97,200 — —
Jan 21, 2026 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +10,000 $1.00 $10,000
Dec 31, 2025 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +9,795 $0.86 $8,424
Dec 30, 2025 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +205 $0.83 $170
Dec 18, 2025 Shaun Bagai Director, Officer (Chief Executive Officer) Open-market purchase +5,000 $0.90 $4,500
Dec 17, 2025 Shaun Bagai Director, Officer (Chief Executive Officer) Open-market purchase +5,000 $0.85 $4,250
Dec 16, 2025 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +12,000 $0.85 $10,200
Dec 5, 2025 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +10,000 $0.96 $9,600
Nov 24, 2025 Ramtin Agah Director, Officer (Chief Medical Officer) Open-market purchase +12,000 $0.80 $9,600

Organizations in the same sector, closest in location and size first.

Questions about RenovoRx Inc.

Who is the CEO of RenovoRx Inc.?

Shaun Bagai is RenovoRx Inc.'s CEO.

How many directors are on RenovoRx Inc.'s board?

RenovoRx Inc.'s board has 7 directors: David Diamond, K. Angela Macfarlane, Laurence Marton, Ramtin Agah, Robert J. Spiegel, Shaun Bagai and Una S. Ryan.

Are RenovoRx Inc. insiders buying or selling shares?

Over the last 12 months, RenovoRx Inc. insiders bought $84,494 of shares in 13 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="renovorx-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.